|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors.
|
31663151 |
2020 |
|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Use of renin-angiotensin system blockers in this setting may increase risk of recurrent AKI.
|
31843974 |
2020 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on experimental and epidemiological pieces of evidence, AKI may progress to chronic kidney disease (CKD) even after a recovery period due to maladaptive repair and other underlying mechanisms such as heightened Wnt signalling, overstimulation of the renin-angiotensin-aldosterone-system (RAAS) pathway, epigenetic alterations and inhibition of hypoxia-inducible factor (HIF) dependent defences.
|
31589870 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Certain medications, such as loop diuretics, renin angiotensin system blockers, and mineralocorticoid antagonists can seemingly cause acute kidney injury.
|
31472814 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations between preoperative continuation of renin-angiotensin system inhibitor and cardiac surgery-associated acute kidney injury: a propensity score-matching analysis.
|
31595420 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rate and Outcome of Acute Kidney Injury Following Hip Fracture Surgery in Diabetic Older Patients Treated with Renin-Angiotensin-Aldosterone Antagonists.
|
30949984 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elderly, patients with chronic kidney disease (CKD) and patients with heart failure who continue using renin-angiotensin-aldosterone-system (RAAS) inhibitors, diuretics, or non-steroidal-anti-inflammatory drugs (NSAIDs) during times of fluid loss have a high risk of developing complications like acute kidney injury (AKI).
|
31801476 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system blocker use and the risk of acute kidney injury after colorectal cancer surgery: a population-based cohort study.
|
31753901 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin system (RAS) inhibitors carry a risk of normotensive ischemic acute kidney injury in dehydration and concurrent nonsteroidal anti-inflammatory drug (NSAID) use.
|
31038268 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fiend and friend in the renin angiotensin system: An insight on acute kidney injury.
|
30554115 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk for AKI with concomitant use of VACV and renin-angiotensin system (RAS) inhibitors that can cause AKI <i>via</i> a similar mechanism to NSAIDs is also unknown.
|
31440161 |
2019 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of renin-angiotensin system in acute kidney injury-chronic kidney disease transition.
|
30298669 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine whether preoperative renin-angiotensin system (RAS) inhibitor use within 7 days of noncardiac surgery is associated with a lower incidence of postoperative acute kidney injury (AKI) in hypertensive patients.
|
29578401 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin-system blockers are thought to increase the risk of acute kidney injury after surgery and hemorrhage.
|
29667909 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Acute kidney injury (AKI) is associated with the activation of the renin-angiotensin system.
|
29766216 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In univariable analyses, CKD [odds ratio (OR) 2.1, 95% confidence interval (CI) 0.99-4.43] and use of renin-angiotensin system (RAS) blockers and/or diuretics (OR 3.85; 95% CI 1.15-20.15) were significantly associated with the risk of AKI.
|
29397541 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined use of drugs inhibiting the renin-angiotensin system: prescribing patterns and risk of acute kidney injury in German nursing home residents.
|
29872281 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Several pathological mechanisms have been proposed to contribute to the progression of AKI and transition to CKD/ESRD including hypoxia and microvascular rarefaction, alterations of renal resident cell phenotypes and functions, cell cycle arrest in the G2/M phase, persistent chronic inflammation, and development of interstitial fibrosis, mitochondrial fragmentation, epigenetic changes, activation of renin-angiotensin system (RAS), cell and tissue senescence.
|
29393158 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relative risk increase is similar across population groups, but the higher baseline risk among those taking renin-angiotensin system blockers and potassium-sparing diuretics translates into higher absolute risks of acute kidney injury and hyperkalaemia in these groups.
|
29438980 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we comment on their findings, exploring the clinical utility of uAGT as a biomarker to predict AKI to CKD transition and perhaps more controversially, to discuss whether the early renin-angiotensin system blockade following AKI represents a therapeutic target.
|
30425169 |
2018 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Animal studies have demonstrated that renin-angiotensin system (RAS) inhibitor can reduce ensuing CKD after functional recovery from AKI.
|
28406186 |
2017 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognostic significance of urinary angiotensinogen as an AKI biomarker strongly suggests a role for renin-angiotensin system activation in modulating the severity of AKI and its outcomes.
|
29225804 |
2017 |
|
Kidney Failure, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, animal studies have shown the activation of renin-angiotensin system (RAS) after AKI.
|
28615146 |
2017 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although protein loading has been established as an ideal method to investigate glomerular filtration capacity in healthy kidneys, other methods such as the antagonism of the renin-angiotensin-aldosterone system have demonstrated promise as a method to determine underlying glomerular disease in those with acute kidney injury and other comorbidities (e.g., congestive heart failure and chronic kidney disease).
|
27820705 |
2017 |
|
Kidney Failure, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
The FDA now requires that AKI be listed as a potential side effect of the SGLT2 inhibitors along with cautious prescription of these drugs with other medications, such as renin-angiotensin-system antagonists, diuretics, and NSAIDs.
|
28637789 |
2017 |